Clinical Trial Update: Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intranasal fluticasone propionate at multiple doses via a novel bidirectional device for bilateral nasal polyposis with an open-label e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bilateral Nasal Polyposis
• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• Fluticasone propionate (intranasal) (fluticasone propionate)

Snippet

Sponsor: Optinose US Inc. | Conditions: Bilateral Nasal Polyposis | Phase 3 | Status: COMPLETED | Results posted: 2018-12-05